Management of Coronary Artery Disease and Conduction Abnormalities in Transcatheter Aortic Valve Implantation

被引：1
作者：
Kostopoulou A. [1 ]
Karyofillis P. [1 ]
Livanis E. [1 ]
Karavolias G. [1 ]
Theodorakis G. [1 ]
Paraskevaides J. [2 ]
Voudris V. [1 ]
机构：
[1] Cardiology Department, Onassis Cardiac Surgery Center, Syngrou av 356, Kallithea, Athens
[2] 2nd University Cardiology Department, Attikon Hospital, University of Athens, Athens
来源：
Current Treatment Options in Cardiovascular Medicine | 2016年 / 18卷 / 2期
关键词：
Aortic valve replacement; Atrioventricular block; Coronary artery disease; Percutaneous coronary intervention; Surgery; Transcatheter aortic valve implantation;
D O I：
10.1007/s11936-015-0432-8
中图分类号：
学科分类号：
摘要：
Transcatheter aortic valve replacement (TAVR) is an expanding, catheter-based technology that allows the implantation of a prosthetic valve without requiring open heart surgery for the treatment of severe aortic stenosis (AS). The frequency of coronary artery disease (CAD) in patients (pts) with severe AS undergoing surgical treatment ranges from 30 to 50 %. This tends to be higher in pts undergoing TAVR with a prevalence of 49–76 % and is more prevalent with older age and the fact that TAVR is commonly performed in high-risk groups with more advanced cardiovascular disease. The overall influence of CAD on TAVR procedural outcomes remains controversial, and the management of concomitant artery disease is still under discussion. There are three major issues that must be addressed: the impact of CAD, optimal timing of percutaneous coronary intervention (PCI) and TAVR, and extent of revascularization. Today, TAVR is commonly performed as a stand-alone procedure with variable degrees of concomitant CAD tolerated without intervention. One of the major potential complications with TAVR is the damage to the conduction system. The requirement of permanent pacemaker (PM) implantation ranges from 9 to 49 % of cases with a mean of ~20 %, whereas surgical aortic valve replacement (sAVR) is associated with a complete heart block that requires permanent PM in 3–12 % of cases. Reports have demonstrated an increased incidence of conduction damage in patients undergoing TAVR with the CoreValve (Medtronic Minneapolis, MN, USA) prosthesis (mean 20.8 %, range 9.3–30.0 %) compared with the Edwards SAPIEN (Edwards Lifesciences LLC; Irvine, CA, USA) prosthesis (mean 5.4 %, range 0–10.1 %). Factors predicting PM implantation include preexisting bundle branch block (BB) or conduction abnormalities. The prognostic significance of new left bundle branch block (LBBB) after TAVR is unclear. In the future, new valve designs may improve the incidence of permanent PM implantation after TAVR. © 2016, Springer Science+Business Media New York.
引用
收藏
页码：1 / 13
页数：12
相关论文
共 59 条
  • [1] Smith C.R., Leon M.B., Mack M.J., Miller D.C., Moses J.W., Svensson L.G., Et al., Transcatheter versus surgical aortic-valve replacement in high-risk patients, N Engl J Med, 364, 23, pp. 2187-2198, (2011)
  • [2] Sehatzadeh S., Doble B., Xie F., Blackhouse G., Campbell K., Kaulback K., Et al., Transcatheter aortic valve implantation (TAVI) for treatment of aortic valve stenosis: an evidence update, Ont Health Technol Assess Ser, 13, 1, pp. 1-40, (2013)
  • [3] Tamburino C., Barbanti M., D'Errigo P., Ranucci M., Onorati F., Covello R.D., Et al., 1-year outcomes after transfemoral transcatheter or surgical aortic valve replacement: results from the Italian OBSERVANT study, J Am Coll Cardiol, 66, 7, pp. 804-812, (2015)
  • [4] Kobayashi J., Changing strategy for aortic stenosis with coronary artery disease by transcatheter aortic valve implantation, Gen Thorac Cardiovasc Surg, 61, 12, pp. 663-668, (2013)
  • [5] Horne A., Reineck E.A., Hasan R.K., Resar J.R., Chacko M., Transcatheter aortic valve replacement: historical perspectives, current evidence, and future directions, Am Heart J, 168, 4, pp. 414-423, (2014)
  • [6] Goel S.S., Ige M., Tuzcu E.M., Ellis S.G., Stewart W.J., Svensson L.G., Et al., Severe aortic stenosis and coronary artery disease—implications for management in the transcatheter aortic valve replacement era: a comprehensive review, J Am Coll Cardiol, 62, 1, pp. 1-10, (2013)
  • [7] Siontis G.C., Juni P., Pilgrim T., Stortecky S., Bullesfeld L., Meier B., Et al., Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: a meta-analysis, J Am Coll Cardiol, 64, 2, pp. 129-140, (2014)
  • [8] Panchal H.B., Ladia V., Desai S., Shah T., Ramu V., A meta-analysis of mortality and major adverse cardiovascular and cerebrovascular events following transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis, Am J Cardiol, 112, 6, pp. 850-860, (2013)
  • [9] Nishimura R.A., Otto C.M., Bonow R.O., Carabello B.A., Erwin J.P., Guyton R.A., Et al., 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Thorac Cardiovasc Surg, 148, 1, pp. e1-e132, (2014)
  • [10] Khawaja M.Z., Asrress K.N., Haran H., Arri S., Nadra I., Bolter K., Et al., The effect of coronary artery disease defined by quantitative coronary angiography and SYNTAX score upon outcome after transcatheter aortic valve implantation (TAVI) using the Edwards bioprosthesis, EuroIntervention, 11, 4, pp. 450-455, (2015)
123456